Insulin-like growth factor-1 and childhood cancer risk.

Overexpression of growth factors and/or their receptors is a common event in malignancy and provides the underlying mechanisms for one of the hallmarks of cancer, uncontrolled proliferation. Mounting evidence suggests that IGF-1 is involved in the pathogenesis and progression of different types of human cancer such as colon, breast, prostate and lung. However, only a few studies have investigated the association between IGF-1 levels and childhood cancer risk. We aimed to compare the IGF-1 serum level in children with de novo malignancies to healthy children, and to assess its relationship with cancer type, stage, metastasis and different disease characteristics. The study was carried out on 100 children; 50 children with de novo malignancies and 50 healthy children of matched age and gender as a control group. The patients were subjected to a routine work-up for their cancers according to our local standards. Estimation of the serum level of IGF-1 was carried out in the two groups using ELISA. Our results showed that children with cancer had significantly higher levels of IGF-1 than healthy controls of the same age and gender. No association was found between IGF-1 and tumor type, stage, metastasis and other disease characteristics. In conclusion, the IGF-1 serum level is an important indicator of risk for the most prevalent forms of childhood cancer. It may be used to identify children at the highest risk for these cancers and aid in determing who may benefit most from preventive strategies. Given the small number of children in our study, studies with larger populations are required to confirm these results.

[1]  M. Franco,et al.  Leukemia, non-Hodgkin's lymphoma, and Wilms tumor in childhood: the role of birth weight , 2010, European Journal of Pediatrics.

[2]  J. Toretsky,et al.  The Role of IGF-1 R in Pediatric Malignancies , 2009 .

[3]  M. Schymura,et al.  Birth weight, maternal weight and childhood leukaemia , 2006, British Journal of Cancer.

[4]  P. Jenkins,et al.  Does growth hormone cause cancer? , 2006, Clinical endocrinology.

[5]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[6]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[7]  L. Robison,et al.  Big babies and infant leukemia: a role for insulin-like growth factor-1? , 1996, Cancer Causes & Control.

[8]  S. Bustin,et al.  The GH–IGF-I axis and breast cancer , 2003, Trends in Endocrinology & Metabolism.

[9]  C. Barozzi,et al.  Relevance of biologic markers in colorectal carcinoma , 2002, Cancer.

[10]  S. Bustin,et al.  The growth hormone-insulin-like growth factor-I axis and colorectal cancer. , 2001, Trends in molecular medicine.

[11]  D. Gunnell,et al.  Cancer and insulin-like growth factor-I , 2000, BMJ : British Medical Journal.

[12]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[13]  T. Yeatman,et al.  Expression of insulin-like growth factor-1 receptor in human colorectal cancer. , 1999, Human pathology.

[14]  G. Davey Smith,et al.  Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? , 1999, The Journal of endocrinology.

[15]  Jack A. Taylor,et al.  Insulin-like growth factor-I: a key regulator of human cancer risk? , 1999, Journal of the National Cancer Institute.

[16]  C. Mantzoros,et al.  Insulin‐like growth factor‐I and binding protein‐3 in relation to childhood leukaemia , 1999, International journal of cancer.

[17]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.

[18]  P. Lollini,et al.  Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.

[19]  L. Helman,et al.  Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. , 1994, American journal of clinical pathology.

[20]  Gwyn T. Williams,et al.  Molecular regulation of apoptosis: Genetic controls on cell death , 1993, Cell.

[21]  V. Sukhatme,et al.  Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Schofield,et al.  Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. , 1993, European journal of cancer.

[23]  N. Dainiak,et al.  Insulin-like growth factors stimulate erythropoiesis in serum-substituted umbilical cord blood cultures. , 1993, Experimental hematology.

[24]  E. Ritzén Does growth hormone increase the risk of malignancies? , 1993, Hormone research.

[25]  G I Bell,et al.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. , 1992, Science.

[26]  Z. Estrov,et al.  Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Steinberg,et al.  Insulin-like growth factor II-mediated proliferation of human neuroblastoma. , 1991, The Journal of clinical investigation.

[28]  D. Yee,et al.  Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. , 1990, The Journal of clinical investigation.

[29]  S. Volkman,et al.  Insulin-like growth factor-I supports proliferation of autocrine thymic lymphoma cells with a pre-T cell phenotype. , 1990, Journal of immunology.

[30]  M. Israel,et al.  Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. , 1989, The Journal of clinical investigation.

[31]  D. Albanes,et al.  Are cell number and cell proliferation risk factors for cancer? , 1988, Journal of the National Cancer Institute.